Full Press Release Details
NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab.
REGN
NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab
Key Takeaway: NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab